로딩 중…
지수 로딩 중…
DAEWOONG PHARMA
069620· KOSPI· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩119,200-1.57%
2026-06-19
Price Chart
DAEWOONG PHARMA-22.90%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 1.38T KRW |
| Revenue | 1.59T KRW |
| Net Income | 199.47B KRW |
| Total Assets | 2.45T KRW |
| Net Assets | 1.15T KRW |
| Employees | 1,757 |
| Value | |
| P/E | 6.92x |
| P/B | 1.20x |
| PEG | 0.42x |
| P/S | 0.87x |
| EV/EBITDA | 78.79x |
| FCF Yield | -3.06% |
| Profitability | |
| ROE | 17.28% |
| ROA | 8.14% |
| Op. Margin | 11.32% |
| Revenue Growth | 5.98% |
| Earnings Growth | 16.52% |
| Financial Health | |
| Debt Ratio | 212.30% |
| Total Debt | 898.04B KRW |
| FCF | -42.33B KRW |
| Cash | 163.66B KRW |
| Current Ratio | 1.12x |
| Net Debt/EBITDA | 27.35x |
| Dividend | |
| Div. Yield | 0.50% |
| Div. Growth | 0.00% |
| Performance | |
| 1Y Return | -22.90% |
| 1M Return | -8.80% |
| From 52W High | -40.22% |
| 1Y MDD | -39.02% |
| Trading | |
| Volume | 21,816 shares |
| Foreign Own. | 15.10% |
| Per Share | |
| EPS | 17,249 KRW |
| BPS | 89,169 KRW |
Company Info
Daewoong Pharmaceutical was established in 2002 as a spin-off from Daewoong Co., Ltd., focusing on pharmaceutical manufacturing and sales. The company operates KGMP-compliant facilities in Hyangnam Industrial Complex, Hwaseong-si, and Osong Bio-Science Complex, Cheongju-si, producing key products like Nabota, Ursa, and Fexuclue. It is advancing global expansion with three innovative new drugs—Fexuclue, Envlo, and Nabota—pursuing a '1 Product, 1 Trillion Won' vision, and growing through digital healthcare investments and new drug development. It is headquartered in Hwaseong-si, Gyeonggi-do.